Close Menu

emergency use authorization

One of the revisions specifies that the ID Now test is for use with specimens collected within the first week of symptom onset.

Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.

Reported as "nucleic acid amplification test-detectable" units per milliliter, the limits of detection of more than 50 commercial tests differed by 10,000-fold.

The test is designed to detect and differentiate SARS-CoV-2, influenza A, and influenza B and runs on the company's benchtop Cobas Liat system.

The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.

The company received Emergency Use Authorization from the US Food and Drug Administration last month for a SARS-CoV-2 total antibody test.

Verily's test is a modified version of Thermo Fisher Scientific's authorized TaqPath COVID-19 Combo Kit that can be used with pooled samples.

The company is currently working on multiple infectious disease products, including a panel for sexually transmitted infections and one for SARS-CoV-2.

Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.

BillionToOne's test is based on the company's proprietary Sanger sequencing approach, while Sugentech's test detects antibodies against SARS-CoV-2.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.